PHILADELPHIA, March 25, 2026 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is continuing to investigate the fairness of the $16.50 per share Select Medical Holdings Corp. (“Select Medical”) (NYSE: SEM) shareholder buyout proposal to determine whether investors are set to receive a high enough price for their shares.  Request additional information here: https://kaskelalaw.com/case/select-medical/   THE TRANSACTION:  On March 2, 2026, Select Medical announced that it had agreed to be acquired by an i ...

Core Viewpoint - Kaskela Law LLC is investigating the fairness of the $16.50 per share buyout offer for Select Medical Holdings Corp. to determine if it undervalues the company's shares [1]. Group 1 - Select Medical announced an agreement to be acquired by an investment consortium on March 2, 2026 [1].

Core Viewpoint - The proposed sale of Select Medical Holdings Corporation to a consortium led by its executives and directors is under investigation by former Attorney General of Louisiana Charles C. Foti, Jr. and the law firm Kahn Swick & Foti, LLC [1] Summary by Relevant Sections - The transaction terms indicate that shareholders will receive $16.50 in cash for each share of Select Medical they own [1]

Core Insights - Select Medical Holdings Corporation (SEM) plans to go private through an acquisition valued at $3.9 billion, led by Executive Chairman Robert Ortenzio and private equity firm Welsh, Carson, Anderson & Stowe, resulting in an 8.4% surge in stock price [1] Company Overview - Shareholders will receive $16.50 per share in cash, which is a 10% premium to the March 2, 2026 closing price and an 18% premium to the November 24, 2025 level, although it is below the average analyst target of $17.70 [2] - The current management is expected to remain in place post-acquisition, which is anticipated to be completed by mid-2026 [3] - As of the end of 2025, Select Medical operated in 39 states and the District of Columbia, focusing on critical illness recovery and rehabilitation services [3] - The company reported a fourth-quarter 2025 adjusted EPS of 16 cents, down 11.1% year over year, while net operating revenues increased by 6.4% to $1.4 billion [3] - Select Medical has a current market cap of $1.86 billion [3] Industry Context - The acquisition comes at a time when healthcare providers face reimbursement pressure and cost volatility, which may allow Select Medical's management to streamline operations and pursue long-term strategic goals outside the public market [4] - Peers like Universal Health Services, Inc. (UHS) and Tenet Healthcare Corporation (THC) are also navigating similar challenges, with UHS facing lower-than-expected admissions and higher operating costs, while THC benefited from stronger revenues but faced rising expenses [5][6] Financial Performance - Select Medical's shares have declined by 9.9% over the past year, underperforming the broader industry and the S&P 500 Index [7] - The Zacks Consensus Estimate for Select Medical's 2026 earnings suggests a 10.3% rise year over year, followed by a projected 17.9% growth in 2027 [10] - The company trades at a forward price-to-earnings ratio of 12.31X, which is higher than the industry average of 11.77X, and carries a Value Score of A [11][12]

Core Viewpoint - Select Medical Holdings Corp. is experiencing significant market activity, with shares rising due to a planned acquisition that will take the company private for $3.9 billion [1][2]. Group 1: Acquisition Details - Select Medical has entered into a definitive agreement for a consortium led by Executive Chairman Robert Ortenzio and Senior Executive Vice President Martin Jackson to acquire all outstanding shares at a price of $16.50 each [2]. - The merger agreement received unanimous approval from the disinterested members of the company's board of directors [2]. - The transaction is expected to close in the middle of the year, pending shareholder approval and other closing conditions [3]. Group 2: Financial Performance - The company reported a net income attributable to shareholders of $20.17 million, a turnaround from a net loss of $16.05 million in 2024 [4]. - Total revenues increased by 7.7 percent year-on-year, reaching $1.4 billion, up from $1.3 billion [4]. - Select Medical is set to distribute dividends of $0.0625 per share to shareholders on record as of March 2, 2026, payable on March 12 [3].

Core Viewpoint - Monteverde & Associates PC is investigating Select Medical Holdings Corporation regarding its proposed sale to a consortium led by its executives and directors, with shareholders expected to receive $16.50 per share in cash, raising questions about the fairness of the deal [1]. Company Summary - Select Medical Holdings Corporation is under scrutiny for its sale to a consortium, which includes its own executives and directors [1]. - The proposed transaction offers Select Medical shareholders a cash payment of $16.50 per share [1]. Legal Context - Monteverde & Associates PC, recognized as a top firm in securities class action services, has a history of recovering millions for shareholders [1]. - The firm is actively seeking information from shareholders who may have concerns regarding the fairness of the proposed transaction [1].

Core Viewpoint - The law firm Brodsky & Smith is investigating potential claims against the Board of Directors of Select Medical Holdings Corporation for possible breaches of fiduciary duty related to the sale of the company for $16.50 per share, which represents an enterprise value of $3.9 billion [1]. Group 1 - The investigation focuses on whether the Select Medical Board failed to conduct a fair process and whether the sale price provides fair value to shareholders, particularly as it is below the 52-week high of $18.61 for the company's shares [2]. - The law firm offers to discuss the legal ramifications of the investigation with shareholders without obligation or cost [3]. Group 2 - Brodsky & Smith is a litigation law firm with expertise in representing shareholders in securities and class action lawsuits, having successfully recovered millions for clients [4].

Group 1 - Select Medical Holdings Corporation is being investigated for its sale to a consortium led by its executives and directors for $16.50 in cash per share [1] - The investigation focuses on whether Select Medical and its board violated federal securities laws and fiduciary duties by not obtaining the best price, failing to conduct a fair sales process, and not disclosing all material information [2] - Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief for shareholders [3]

Group 1 - Ademi LLP is investigating Select Medical Holdings Corporation for potential breaches of fiduciary duty and other legal violations related to a transaction with a consortium led by Executive Chairman Robert A. Ortenzio and private equity firm Welsh, Carson, Anderson & Stowe [1] - The transaction involves Select Medical stockholders receiving $16.50 per share in cash, with an enterprise value of approximately $3.9 billion [1] - The transaction agreement imposes significant penalties on Select Medical for accepting competing bids, raising concerns about the board's fulfillment of fiduciary duties to all shareholders [1]

Core Viewpoint - Select Medical Holdings Corporation has entered into a definitive merger agreement with a consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe (WCAS) to acquire all outstanding shares of Select Medical not already owned by the consortium for $16.50 per share, representing an enterprise value of $3.9 billion [1]. Group 1: Merger Agreement Details - The merger consideration of $16.50 per share represents an approximate 18% premium over Select Medical's unaffected share price as of November 24, 2025, and a 25% premium over the 90-day volume-weighted average closing share price for the same period [1]. - The merger agreement was unanimously approved by the disinterested members of Select Medical's Board of Directors, following a recommendation from a special committee of independent directors [1]. - The merger is expected to close in mid-2026, subject to customary closing conditions, including approval by a majority of votes from unaffiliated shareholders and necessary regulatory approvals [1]. Group 2: Company Operations and Management - Select Medical will continue to operate normally during the merger process, maintaining its commitment to patients, employees, and partners, with current management expected to remain in place post-merger [1]. - As of December 31, 2025, Select Medical operated 104 critical illness recovery hospitals, 38 rehabilitation hospitals, and 1,917 outpatient rehabilitation clinics across 39 states and the District of Columbia [2]. Group 3: Consortium and Financial Advisors - The consortium includes key figures from Select Medical and WCAS, a private equity firm focused on technology and healthcare, which has raised over $33 billion in committed capital since its founding in 1979 [2]. - J.P. Morgan and Wells Fargo are serving as joint lead arrangers for the debt financing of the consortium, while Goldman Sachs is the exclusive financial advisor to the special committee [1].